MedTrace Logo

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

NCT00346697 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2014-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation.

Conditions

Interventions

DRUG

Omega-3 fatty acid administration

LOVAZA 1 gram capsules, 4 capsules daily

DRUG

Placebo

Corn-oil placebo

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Brown, Todd, M.D., Ph.D.

    lead INDIV

Principal Investigators

  • Todd T. Brown, MD · Johns Hopkins University

  • David Leaf, MD · Veterans Adminstration of Greater Los Angeles Health System

  • Mattew Goetz, MD · Veterans Adminstration of Greater Los Angeles Health System

  • Adrian S Dobs, MD · Johns Hopkins University

  • Joseph Timpone, MD · Georgetown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346697 on ClinicalTrials.gov